Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

The structural and health policy environment for delivering integrated HIV and substance use disorder treatments in Puerto Rico.

Leff JA, Hernández D, Teixeira PA, Castellón PC, Feaster DJ, Rodriguez AE, Santana-Bagur JL, De León SM, Vidot JV, Metsch LR, Schackman BR.

BMC Health Serv Res. 2017 Mar 23;17(1):232. doi: 10.1186/s12913-017-2174-7.

2.

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M; ION-4 Investigators.

N Engl J Med. 2015 Aug 20;373(8):705-13. doi: 10.1056/NEJMoa1501315. Epub 2015 Jul 21.

3.

Metabolic syndrome in relation to cardiorespiratory fitness, active and sedentary behavior in HIV+ Hispanics with and without lipodystrophy.

Ramírez-Marrero FA, Santana-Bagur JL, Joyner MJ, Rodríguez-Zayas J, Frontera W.

P R Health Sci J. 2014 Dec;33(4):163-9.

4.

Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229.

McComsey GA, Walker UA, Budhathoki CB, Su Z, Currier JS, Kosmiski L, Naini LG, Charles S, Medvik K, Aberg JA; AIDS Clinical Trials Group A5229 Team.

AIDS. 2010 Oct 23;24(16):2507-15. doi: 10.1097/QAD.0b013e32833ea9bc.

5.

AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.

Schooley RT, Spritzler J, Wang H, Lederman MM, Havlir D, Kuritzkes DR, Pollard R, Battaglia C, Robertson M, Mehrotra D, Casimiro D, Cox K, Schock B; AIDS Clinical Trials Group 5197 Study Team.

J Infect Dis. 2010 Sep 1;202(5):705-16. doi: 10.1086/655468.

6.

Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial.

Flexner C, Tierney C, Gross R, Andrade A, Lalama C, Eshleman SH, Aberg J, Sanne I, Parsons T, Kashuba A, Rosenkranz SL, Kmack A, Ferguson E, Dehlinger M, Mildvan D; ACTG A5073 Study Team.

Clin Infect Dis. 2010 Apr 1;50(7):1041-52. doi: 10.1086/651118.

7.

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.

Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M, Peeters M, Picchio G, Vingerhoets J, Woodfall B, De Smedt G; DUET-1, DUET-2 study groups.

AIDS. 2009 Nov 13;23(17):2289-300. doi: 10.1097/QAD.0b013e3283316a5e.

PMID:
19710593
8.

Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.

Gross R, Tierney C, Andrade A, Lalama C, Rosenkranz S, Eshleman SH, Flanigan T, Santana J, Salomon N, Reisler R, Wiggins I, Hogg E, Flexner C, Mildvan D; AIDS Clinical Trials Group A5073 Study Team.

Arch Intern Med. 2009 Jul 13;169(13):1224-32. doi: 10.1001/archinternmed.2009.172.

9.

Physical and leisure activity, body composition, and life satisfaction in HIV-positive Hispanics in Puerto Rico.

Ramírez-Marrero FA, Smith BA, Meléndez-Brau N, Santana-Bagur JL.

J Assoc Nurses AIDS Care. 2004 Jul-Aug;15(4):68-77.

PMID:
15296660

Supplemental Content

Loading ...
Support Center